Sigrima 420mg Injection: Uses, Benefits, Side Effects & FAQs

Sigrima 420mg Injection (Pertuzumab) is a targeted cancer therapy used under specialist medical supervision for certain types of HER2-positive breast cancer. It contains pertuzumab, a monoclonal antibody that targets the HER2 protein involved in the growth of some breast cancer cells. Sigrima is administered intravenously by a qualified healthcare professional and is generally used in combination with other prescribed cancer medicines.

Cordium Pharmaceuticals Pvt. Ltd. provides pharmaceutical product information to support awareness among healthcare professionals, patients, and international pharmaceutical trade partners. Product availability, approved indications, and supply conditions may vary by country.

Uses of Sigrima 420mg Injection

Sigrima 420mg Injection may be prescribed as part of a combination treatment plan for eligible patients with HER2-positive breast cancer, including:

Early-stage breast cancer: In selected cases, treatment may be given before surgery or after surgery alongside trastuzumab and chemotherapy.

Metastatic breast cancer: It may be used with trastuzumab and docetaxel for eligible patients whose HER2-positive breast cancer has spread to other parts of the body.

Treatment suitability depends on HER2 test results, cancer stage, previous treatment, and the patient's overall health. An oncologist must determine whether this medicine is appropriate.

Benefits of Sigrima 420mg Injection

1. Targeted HER2 therapy: Pertuzumab binds to the HER2 receptor and interferes with signals that promote cancer cell growth.

2. Combination treatment approach: When prescribed with trastuzumab and appropriate chemotherapy, Sigrima can contribute to a treatment strategy designed for specific HER2-positive breast cancers.

3. Support for individualised cancer care: Its use in eligible patients may help improve disease control and treatment outcomes. Benefits vary according to the diagnosis, treatment regimen, and individual response.

Sigrima is not a cure for every type of breast cancer and should only be used according to an oncologist's treatment plan.

Side Effects of Sigrima 420mg Injection

Possible side effects include diarrhoea, nausea, vomiting, tiredness, hair loss, rash, muscle pain, headache, and reduced blood cell counts, particularly when Sigrima is administered with chemotherapy.

Serious risks include reduced heart function, severe infusion-related reactions, and serious allergic reactions. Seek urgent medical attention for breathing difficulties, facial or throat swelling, fainting, or new or worsening symptoms suggestive of heart problems.

Before treatment, inform your healthcare professional about existing heart conditions, allergies, pregnancy, breastfeeding, and all medicines you take. Treatment may require heart-function assessments and other monitoring. Sigrima can harm an unborn baby; discuss effective contraception and pregnancy planning with your oncologist.

Frequently Asked Questions (FAQs)

1. What is Sigrima 420mg Injection used for?

It is used with other cancer medicines to treat certain types of HER2-positive breast cancer in eligible patients.

2. What is the active ingredient in Sigrima?

The active ingredient is pertuzumab, a monoclonal antibody used in targeted cancer therapy.

3. How is Sigrima 420mg Injection administered?

A trained healthcare professional administers it through an intravenous infusion according to the prescribed treatment schedule. It must not be self-administered.

4. What are the common side effects?

Diarrhoea, nausea, fatigue, hair loss, rash, and muscle pain may occur. Side effects can vary depending on the combination treatment.

5. How should Sigrima be stored?

Follow the product label and local prescribing information. The marketed presentation is refrigerated at 2–8°C and must not be frozen.

6. Can Sigrima be purchased without a prescription?

No. It is a specialist prescription medicine and should be obtained through authorised pharmaceutical channels in accordance with local regulations.

Important Medical Disclaimer

This page is for general educational and product-information purposes only. It does not replace medical advice, diagnosis, or treatment. Use Sigrima only under the supervision of a qualified oncologist and consult the locally approved prescribing information.